Institution
UCSF Helen Diller Family Comprehensive Cancer Center
Also known as: HDFCCC
- 41running trials
- 21closed trials
- 10,135publications (OpenAlex)
Running trials
Not yet recruiting
NANT 2021-02: Randomized MIBG With Vorinostat/Dinutuximab/Vorinostat + Dinutuximab
Enrolling by invitation
Recruiting
A Study to Evaluate OPB-201 in Recurrent Endometrial and Platinum-resistant Ovarian Cancer.
Recruiting
Recruiting
Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors
Recruiting
Phase 1/2 Dose Finding, Safety and PK Study in Advanced Refractory Solid Tumors
Recruiting
COMPASS Study for Metastatic Castration-resistant Prostate Cancer
Recruiting
Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors
Recruiting
Recruiting
Recruiting
Active, not recruiting
Quizartinib or Placebo Plus Chemotherapy in Newly Diagnosed Patients With FLT3-ITD Negative AML
Recruiting
A First-in-Human Study of MEN2312 in Adults With Advanced Breast Cancer
Recruiting
Recruiting
Safety and Tolerability Study of GIM-531 in Advanced Solid Tumors
Recruiting
A Study to Investigate the Safety and Efficacy of NST-628 Oral Tablets in Subjects With Solid Tumors
Active, not recruiting
Copper Cu 64 PSMA I&T PET Imaging in Men With Newly Diagnosed Prostate Cancer
Active, not recruiting
Active, not recruiting
Active, not recruiting
Recruiting
Active, not recruiting
Active, not recruiting
Recruiting
Study of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer (ENGAGER-PSMA-01)
Recruiting
Recruiting
A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors
Active, not recruiting
Recruiting
A Study of Targeted Agents for Patients With Recurrent or Persistent Endometrial Cancer
Active, not recruiting
Recruiting
Study to Evaluate VT3989 in Patients With Metastatic Solid Tumors
Recruiting
Recruiting
Treatment of Radiation and Cisplatin Induced Toxicities with Tempol
Active, not recruiting
Immunotherapy of Relapsed Refractory Neuroblastoma With Expanded NK Cells
Active, not recruiting
Active, not recruiting
Active, not recruiting
Active, not recruiting
Matched Targeted Therapy For High-Risk Leukemias and Myelodysplastic Syndrome
Recruiting
Active, not recruiting
Active, not recruiting
Diagnostic Study of Patients With Acute Lymphoblastic Leukemia or Acute Promyelocytic Leukemia
Active, not recruiting
Recruiting at the same time
How many trials recruit for the same indication here at once. A count, not a rating.
- Childhood cancers5 recruiting
- Lung cancer5 recruiting
- Melanoma5 recruiting
- Ovarian cancer4 recruiting
- Prostate cancer4 recruiting
- Endometrial cancer3 recruiting
- Colorectal cancer2 recruiting
- Metastatic breast cancer2 recruiting
- Neuroblastoma2 recruiting
- Triple-negative breast cancer2 recruiting
- Acute myeloid leukaemia1 recruiting
- Bladder cancer1 recruiting
- Cervical cancer1 recruiting
- Gastric and oesophageal cancer1 recruiting
- Head and neck cancer1 recruiting
- Liver and biliary tract cancer1 recruiting
- Mesothelioma1 recruiting
- Myelodysplastic syndromes1 recruiting
- Neuroendocrine tumours1 recruiting
- Pancreatic cancer1 recruiting
- Thyroid cancer1 recruiting
Closed trials
Recruiting
Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors
Terminated
Terminated
Safety and Effectiveness of ABM-168 in Adults with Advanced Solid Tumors.
Terminated
Completed
Terminated
Terminated
Study of PF-07265807 in Participants With Metastatic Solid Tumors.
Completed
Completed
Completed
A Phase 1 Study of FOR46 in Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Completed
Completed
Completed
Study of 177Lu-PSMA-617 In Metastatic Castrate-Resistant Prostate Cancer
Terminated
Withdrawn
Radiation Therapy and Durvalumab, With or Without Tremelimumab, in Patients With Bladder Cancer
Completed
Completed
Completed
Completed
Endocrine Response in Women With Invasive Lobular Breast Cancer
Completed
Completed
Radiation Therapy With Cisplatin or Cetuximab in Treating Patients With Oropharyngeal Cancer
Registry name variants (6)
Trial registries list this institution under these names. Each row is one registry entry: its address and the trials registered under it.
UCSF Helen Diller Family Comprehensive Cancer Center
San Francisco, California 94158
57 trials
UCSF Helen Diller Family Comprehensive Cancer Center (Site 0016)
San Francisco, California 94158
1 trial
UCSF Helen Diller Family Comprehensive Cancer Center (Site 0056)
San Francisco, California 94158
1 trial
UCSF Helen Diller Family Comprehensive Cancer Center (Site 0704)
San Francisco, California 30322
1 trial
UCSF Helen Diller Family Comprehensive Cancer Centre
San Francisco, California 94158
1 trial
UCSF- San Francisco (Helen Diller Family Comprehensive Cancer Center)
San Francisco, California 94158
1 trial
Contact: Rahul Aggarwal, MD (principal investigator)
Conditions
Diseases this institution publishes on or runs trials for.
- Prostate cancer58 works · 9 trials
- Bladder cancer28 works · 6 trials
Institution data: ROR 05yndxy10 (CC0-1.0)Updated 15 Nov 2026